Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Tazemetostat in Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
jRCT2080223431Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tazemetostat in mature B-cell lymphoma, sponsored by Eisai Co., Ltd. Primary endpoints: Safety and tolerability of tazemetostat and Pharmacokinetics of tazemetostat. Started Jan 2017; status: completed.
02
Drugs
tazemetostat
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on jRCT2080223431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223431.